Innospec's fortress balance sheet (D/E of 0.04, $250.2M cash) and stable gross margins near 28% provide a solid foundation, while recent revenue growth of 11.8% in 2026Q2 suggests a potential inflection. However, persistent working capital swings (ranging from...
Price trend, volume and key moving averages
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 4, 2026 | $1.27+21.0% vs $1.05 | $491M+7.5% vs $457M |
Q2 2026 May 7, 2026 | $1.05+2.9% vs $1.02 | $453M+4.9% vs $432M |
Q1 2026 Feb 17, 2026 | $1.50+19.0% vs $1.26 | $456M-1.1% vs $461M |
Q4 2025 Nov 4, 2025 | $1.12+8.7% vs $1.03 | $442M-4.1% vs $461M |
Squarepoint Ops LLC cut its stake in Innospec Inc. (NASDAQ: IOSP) by 37.0% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,379 shares of the specialty chemicals company's stock after selling 6,107 shares during the quarter. Squarepoint Ops LLC's
Innospec (IOSP) reported earnings 30 days ago. What's next for the stock?
The Zacks Chemicals Diversified is expected to benefit from healthy demand across major end-use markets and the end of destocking activities. APD, DD, AVNT and IOSP are set to gain from strategic actions and demand recovery.
With the oilfield segment leading topline growth, even more growth should be expected as the adoption of DRA expands and the firm re-enters the Mexico market. In Q2 of 2026, revenue grew 12%, beating estimates by $34.17 million. The firm is now in a better financial position to command a higher sales multiple. The Performance chemical segment still experiences volume declines, raising concerns about the firm over investing by adding 10% capacity in a weak market.
Benchmark IOSP against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Innospec Inc. (IOSP)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $96.08 | $2.37B | 20.57 | -3.65% | 6.56% | 9.15% | 1.77% | |
| $124.55 | $2.6B | 31.85 | 11.21% | 7.29% | 15.3% | — | |
| $168.40 | $5.41B | 35.45 | 8.75% | 15.14% | 12.79% | — | |
| $292.86 | $552.92M | 15.77 | 5.6% | 13.8% | 14.63% | — | |
| $159.47 | $2.77B | -1139.07 | 2.66% | 4.94% | 7.1% | — | |
| $79.47 | $4.1B | 13.20 | -7.04% | 5.23% | 11.09% | — |
Innospec Inc. (IOSP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Innospec Inc. (IOSP) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 5, 2026·SEC
Jun 4, 2026·SEC
May 13, 2026·SEC
Get notified when IOSP posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Innospec Inc. (IOSP) stock FAQ — growth, dividends, profitability & financials explained
Innospec Inc. (IOSP) reported $1.84B in revenue for fiscal year 2025. This represents a 296% increase from $465.0M in 1998.
Innospec Inc. (IOSP) saw revenue decline by 3.7% over the past year.
Yes, Innospec Inc. (IOSP) is profitable, generating $121.5M in net income for fiscal year 2025 (6.6% net margin).
Yes, Innospec Inc. (IOSP) pays a dividend with a yield of 1.77%. This makes it attractive for income-focused investors.
Innospec Inc. (IOSP) has a return on equity (ROE) of 9.1%. This is below average, suggesting room for improvement.
Innospec Inc. (IOSP) generated $64.9M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
